Deuterohemin-AlaHisLys mitigates the symptoms of rats with non-insulin dependent diabetes mellitus by scavenging reactive oxygen species and activating the PI3-K/AKT signal transduction pathway

Mesoporous molecularly imprinted nanoparticles with peptide mimics for the detection of phenolic compounds

Immobilized enzymes outperform free enzymes in many properties and are widely used in environmental monitoring, engineering applications, food and medical fields. Based on the developed immobilization techniques, the search for immobilization with wider applicability, lower cost and more stable enzyme properties is of significant importance. In this study, we reported a molecular imprinting strategy for immobilizing peptide mimics of DhHP-6 on mesoporous materials. The DhHP-6 molecularly imprinted polymer (MIP) showed much higher adsorption capacity than raw mesoporous silica toward DhHP-6. The DhHP-6 peptide mimics was immobilized on the surface of mesoporous silica for the fast detection of phenolic compounds, a widely spread pollutant with highly toxic and difficult in degradation. Immobilized enzyme of DhHP-6-MIP exhibited higher peroxidase activity, better stability, and recyclability than free peptide. Notably, DhHP-6-MIP showed excellent linearity for the detection of the two phenols with detection limits of 0.28 μM and 0.25 μM, respectively. In combination with the spectral analysis and PCA method, DhHP-6-MIP provided better discrimination between the six phenolic compounds (phenol, catechol, resorcinol, hydroquinone, 2-chlorophenol, 2, 4-dichlorophenol). Our study showed that immobilization of peptide mimics by the molecular imprinting strategy using mesoporous silica as carriers was a simple and effective approach. The DhHP-6-MIP has great potentiality for the monitoring and degradation of environmental pollutants.

DhHP-6 ameliorates hepatic oxidative stress and insulin resistance in type 2 diabetes mellitus through the PI3K/AKT and AMPK pathway

Insulin resistance is one major features of type 2 diabetes mellitus (T2DM). Deuterohemin-βAla-His-Thr-Val-Glu-Lys (DhHP-6), a novel microperoxidase mimetic designed and synthesized based on microperoxidase 11 (MP-11), can scavenge reactive oxygen species (ROS) in vivo. In our previous studies, we showed that oral DhHP-6 could reduce blood glucose and improve insulin resistance. To investigate the mechanisms of how DhHP-6 ameliorates oxidative stress and insulin resistance, we established T2DM mouse models and glucosamine-induced HepG2 cell insulin resistance models. The results suggested that DhHP-6 decreased blood glucose, increased antioxidant enzyme activity, and inhibited glycogen synthesis in T2DM mice. In addition, DhHP-6 improved insulin resistance by activating phosphatidylinositol 3-kinase (PI3K)/AKT, and AMP-activated protein kinase (AMPK) pathway in T2DM mice. Furthermore, DhHP-6 also activated PI3K/AKT and AMPK pathway in glucosamine-induced HepG2 cells. However, LY294002 did not completely inhibit AKT phosphorylation, and partially inhibited AMPK phosphorylation, whilst compound C only partially reduced AMPK phosphorylation, and also partially inhibited AKT phosphorylation, suggesting that AKT and AMPK interact to improve insulin resistance. Thus, these data suggest that DhHP-6 attenuates insulin resistance via the PI3K/AKT and AMPK pathway.

Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1/PD-L1 axis

Blockade of the PD-1/PD-L1 axis using antibody drugs has been a clinically efficacious immunotherapy in cancer treatment. However, studies on peptide inhibitors blocking the interaction between PD-1/PD-L1 in cancer treatment in clinical practice have not yet been reported. In this study, a series of peptide inhibitors were synthesized based on a continuous sequence of 14 amino acids from PD-L1 and suitable modifications to form a hairpin structure. The effect of inhibitors on the blockage of PD-1/PD-L1 by increasing the stability of the hairpin structure was determined using BLI and co-culture models. The results showed that increasing the stability of the hairpin improved the affinity of inhibitors to PD-1 and increased IL-2 secretion. Therefore, modifying the hairpin structure of peptide inhibitors may be a useful approach to block the interaction between PD-1 and PD-L1.

Activity adaptability of a DhHP-6 peroxidase-mimic in wide pH and temperature ranges and solvent media

Deuterohemin-β-Ala-His-Thr-Val-Glu-Lys (DhHp-6): peroxidase with high activity.

Oral DhHP-6 for the Treatment of Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) is associated with pancreatic β-cell dysfunction which can be induced by oxidative stress. Deuterohemin-βAla-His-Thr-Val-Glu-Lys (DhHP-6) is a microperoxidase mimetic that can scavenge reactive oxygen species (ROS) in vivo. In our previous studies, we demonstrated an increased stability of linear peptides upon their covalent attachment to porphyrins. In this study, we assessed the utility of DhHP-6 as an oral anti-diabetic drug in vitro and in vivo. DhHP-6 showed high resistance to proteolytic degradation in vitro and in vivo. The degraded DhHP-6 product in gastrointestinal (GI) fluid retained the enzymatic activity of DhHP-6, but displayed a higher permeability coefficient. DhHP-6 protected against the cell damage induced by H₂O₂ and promoted insulin secretion in INS-1 cells. In the T2DM model, DhHP-6 reduced blood glucose levels and facilitated the recovery of blood lipid disorders. DhHP-6 also mitigated both insulin resistance and glucose tolerance. Most importantly, DhHP-6 promoted the recovery of damaged pancreas islets. These findings suggest that DhHP-6 in physiological environments has high stability against enzymatic degradation and maintains enzymatic activity. As DhHP-6 lowered the fasting blood glucose levels of T2DM mice, it thus represents a promising candidate for oral administration and clinical therapy.

The Effect of Tianmai Xiaoke Pian on Insulin Resistance through PI3-K/AKT Signal Pathway

In the clinical setting, given the potential adverse effects of thiazolidinediones and biguanides, we often have difficulty in treatment that no other insulin sensitizers are available for use in type 2 diabetic mellitus (T2DM) patients. Tianmai Xiaoke Pian (TMXKP) is a traditional Chinese medicine tablet, which is comprised of chromium picolinate, Tianhuafen, Maidong, and Wuweizi. To understand its mechanism of action on insulin resistance, TMXKP (50 mg/kg orally) was tested in T2DM rats (induced by a high-fat diet and streptozotocin). Eight weeks later, fasting blood glucose (FBG) and oral glucose tolerance tests (OGTT) were performed. Area under the curve (AUC) and homeostatic model assessment of insulin resistance (HOMA-IR) were calculated, and PI3-K/AKT signal pathway-related genes and proteins were tested by reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis in muscle, adipose, and liver tissues, respectively. TMXKP significantly reduced FBG, OGTT, AUC, and HOMA-IR in diabetic rats (P < 0.05). Furthermore, we also observed that TMXKP could significantly decrease IRS-1, IRS-2, PI3-K p85α, and AKT2 gene expression and also IRS-1, IRS-2, PI3-K, AKT2, and p-AKT2 protein expression levels (P < 0.05) in diabetic rats. These findings confirm that TMXKP can alleviate insulin resistance in T2DM rats through the PI3K/AKT pathway. Thus TMXKP appears to be a promising insulin sensitizer.